Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Eur J Intern Med. 2019 Feb;60:46-53. doi: 10.1016/j.ejim.2018.10.013. Epub 2018 Oct 23.
The aim of our study was to define the role of high-sensitive cardiac troponin T (hs-cTnT) and NT-proBNP in identifying Systemic Sclerosis (SSc) patients with cardiac involvement and at higher risk of cardiac death.
Plasma hs-cTnT and NT-proBNP concentrations were measured in 245 SSc-patients.
hs-cTnT and NT-proBNP levels were higher in SSc-patients than in healthy controls. Hs-cTnT levels were higher than 0.014 ng/ml in 32.3% SSc-patients, while NT-proBNP was above 125 pg/ml in 31.8% of them, irrespective of classical cardiovascular risk factor and of pulmonary arterial hypertension. Elevated hs-cTnT and NT-proBNP were associated with diffuse skin involvement and directly correlated with the skin score. Patients with increased cardiac markers presented a lower left-ventricular ejection fraction (LVEF) and a higher rate of right bundle branch block (RBBB) on electrocardiogram (ECG) compared to patients with normal cardiac enzymes. During the follow-up, 12 SSc-patients experience a disease-related death; 9 of these were directly related to cardiac involvement (sudden cardiac death or heart failure) and the majority of them occurred among patients with increase of at least one cardiac biomarker. Long-term survival was worse in patients with increase of both cardiac biomarkers.
Evaluation of hs-cTnT and NT-proBNP levels may provide a tool to screen non-invasively SSc-patients for heart involvement. A higher incidence of impaired systolic function, ECG abnormalities and a poor outcome in SSc-patients with elevated cardiac enzymes suggests that they may be valuable screening biomarkers to detect a cardiac damage at early stages and to improve risk stratification.
本研究旨在确定高敏心肌肌钙蛋白 T(hs-cTnT)和 NT-proBNP 在识别有心脏受累和更高心脏死亡风险的系统性硬化症(SSc)患者中的作用。
测量了 245 名 SSc 患者的血浆 hs-cTnT 和 NT-proBNP 浓度。
与健康对照组相比,SSc 患者的 hs-cTnT 和 NT-proBNP 水平更高。32.3%的 SSc 患者 hs-cTnT 水平高于 0.014ng/ml,31.8%的患者 NT-proBNP 高于 125pg/ml,无论是否存在经典心血管危险因素和肺动脉高压。hs-cTnT 和 NT-proBNP 升高与弥漫性皮肤受累有关,并与皮肤评分直接相关。与正常心肌酶患者相比,hs-cTnT 和 NT-proBNP 升高的患者左心室射血分数(LVEF)较低,心电图(ECG)上右束支传导阻滞(RBBB)的发生率较高。在随访期间,12 名 SSc 患者发生与疾病相关的死亡;其中 9 例与心脏受累直接相关(心源性猝死或心力衰竭),且多数发生在至少一种心脏生物标志物升高的患者中。hs-cTnT 和 NT-proBNP 均升高的患者长期生存率较差。
hs-cTnT 和 NT-proBNP 水平的评估可能为筛查 SSc 患者的心脏受累提供一种非侵入性工具。hs-cTnT 和 NT-proBNP 升高的 SSc 患者收缩功能受损、心电图异常发生率更高,预后更差,这表明它们可能是有价值的筛查生物标志物,可在早期发现心脏损伤,并改善风险分层。